AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26097986
Drug: AZD3043 1-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3043 1-minute bolus followed by 30-minute infusion (0.8 + 10, 1 + 15, 3 + 30, and 4 + 40 mg/kg)
Trial: 26098143
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon β-1a (Rebif®, Merck Serono SA) 44 or 22 μg three times weekly
Trial: 26098215
Drug: Fresolimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresolimumab (1 mg/kg, 2 doses)
Trial: 26098215
Drug: Fresolimumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresolimumab (5 mg/kg, 1 dose)
Trial: 26098748
Drug: Buparlisib (BKM120)
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (BKM120) 100 mg/day
Trial: 26100711
Drug: Paritaprevir-ritonavir dose
RxNorm normalized name: ombitasvir / paritaprevir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paritaprevir-ritonavir dose of 150/100 mg
Trial: 26100711
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration of 12 or more weeks
Trial: 26100711
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration of 8 weeks
Trial: 26101247
Drug: Letrozole 5
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 5 mg per day with ovarian stimulation and embryo cryopreservation
Trial: 26103565
Drug: Home-based telemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based telemental health treatment (behavioral activation treatment)
Trial: 26103598
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg day(-1))
Trial: 26105029
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about medications and patient adherence profiles
Trial: 26105149
Drug: Initiating treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiating treatment at diagnosis
Trial: 26108094
Drug: Laboratory evaluation
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laboratory evaluation and questionnaire administration
Trial: 26109588
Drug: guided high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guided high MI/half tPA (0.5 mg/kg tPA with guided high MI impulses)
Trial: 26109588
Drug: full-dose tPA
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: full-dose tPA (1.0 mg/kg tPA)
Trial: 26109588
Drug: half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half dose tPA (control group)
Trial: 26109588
Drug: full-dose tPA
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: full-dose tPA
Trial: 26109631
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m(2)), Cisplatin (75 mg/m(2)), and Cetuximab (250 mg/m(2) weekly with a loading dose of 400 mg/m(2)), followed by maintenance Cetuximab (500 mg/m(2) every 2 weeks)
Trial: 26111297
Drug: Fecal ELISA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal ELISA assay for G intestinalis
Trial: 26112004
Drug: Oraxol (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraxol (paclitaxel 150 mg/m(2) per day + HM30181A 15 mg/day)
Trial: 26112099
Drug: Self-administered icatibant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered icatibant
Trial: 26112099
Drug: HCP-administered icatibant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCP-administered icatibant
Trial: 26112223
Drug: Empiric oral
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric oral antibiotic therapy
Trial: 26115532
Drug: Unwanted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unwanted treatment (any of the above therapies) in comorbidly depressed patients
Trial: 26115532
Drug: Treatment preference/disinclination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference/disinclination
Trial: 26115532
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment preference
Trial: 26116126
Drug: GSK1034702 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1034702 (5 mg oral dose)
Trial: 26116126
Drug: [(11)C]GSK1034702 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(11)C]GSK1034702 (intravenous injection)
Trial: 26116238
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with Paclitaxel and Trastuzumab for HER2-positive patients
Trial: 26116238
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with Docetaxel and Epirubicin for HER2-negative patients
Trial: 26116658
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 1; n = 27)
Trial: 26116658
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 2; n = 20)
Trial: 26116658
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (Group 3; n = 24)
Trial: 26116658
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg daily and 12 doses of ofatumumab 300/2000 mg (all groups)
Trial: 26119560
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guérin (BCG) administered according to the Southwest Oncology Group protocol.
Trial: 26123421
Drug: Impulse oscillometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled methacholine
Trial: 26123421
Drug: Impulse oscillometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impulse oscillometry (IOS) during bronchial challenge testing with inhaled histamine
Trial: 26123421
Drug: Spirometry (FEV1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirometry (FEV1) during bronchial challenge testing with inhaled methacholine
Trial: 26123926
Drug: Tivantinib (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (360 mg po bid)
Trial: 26123937
Drug: Single-tablet FTC-RPV-TDF
RxNorm normalized name: (-)-FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tablet FTC-RPV-TDF once daily for 28 days
Trial: 26132314
Drug: Rituximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (500 mg/m2), two infusions two weeks apart, followed by maintenance infusions after 3, 6, 10 and 15 months
Trial: 26133566
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg of ceftazidime + 500 mg of avibactam
Trial: 26133566
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg of ceftazidime + 1000 mg of avibactam
Trial: 26134834
Drug: Aggressive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aggressive insulin delivery setting
Trial: 26134834
Drug: Medium insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium insulin delivery setting
Trial: 26134834
Drug: Conservative insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conservative insulin delivery setting
Trial: 26135098
Drug: Polyethylene glycol-based
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-based electrolyte solutions (PEG-ELS)
Trial: 26135681
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy in R1 patients
Trial: 26135770
Drug: Threshold of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold of IMA >163 ng/mL
Trial: 26137304
Drug: 25(OH)D ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D ≥ 75 nmol/L
Trial: 26137358
Drug: Desvenlafaxine 25
RxNorm normalized name: DESVENLAFAXINE 25 mg ORAL TABLET, EXTENDED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 25 mg/d for 1 week followed by placebo for 3 weeks (taper)
Trial: 26137358
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 4 weeks (abrupt discontinuation)
Trial: 26137358
Drug: Desvenlafaxine 50
RxNorm normalized name: desvenlafaxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 50 mg/d for 4 weeks (no discontinuation)
Trial: 26137532
Drug: Escitalopram, sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, sertraline or venlafaxine-ER for 8 weeks
Trial: 26137971
Drug: Clindamycin and
RxNorm normalized name: clindamycin and benzoyl peroxide KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and metronidazole followed by vaginal EcoVag® capsules for 5 consecutive days after each antibiotic treatment.
Trial: 26137971
Drug: Clindamycin and
RxNorm normalized name: clindamycin and benzoyl peroxide KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and metronidazole treatment together with prolonged administration of EcoVag® (10 consecutive days after each antibiotic treatment followed by weekly administration for next four months).
Trial: 26137971
Drug: Extended fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended fluconazole and EcoVag® treatment.
Trial: 26137971
Drug: Extended fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended fluconazole treatments only.
Trial: 26139558
Drug: MABp1 (1.25mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MABp1 (1.25mg/kg body weight, four biweekly intravenous infusions)
Trial: 26140502
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n = 40)
Trial: 26140502
Drug: Treatment crossover
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment crossover (n = 20)
Trial: 26141713
Drug: Pressure from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure from doctors to reduce the delay between diagnosis and cancer treatment
Trial: 26143264
Drug: Melanoma GVAX
RxNorm normalized name: Melanoma GVAX
DrugBank: GVAX (DB17276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma GVAX (5E7 cells/cycle, 2E8 cells/cycle, or 2E8 cells/cycle with cyclophosphamide 200 mg/m2) administered intradermally once every 28 days for four cycles
Trial: 26143343
Drug: Intravenous Sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Sildenafil
Trial: 26148006
Drug: CLI patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLI patients not using aspirin
Trial: 26148750
Drug: Icotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg orally 3 times/day) + Whole-Brain Radiotherapy (WBRT, 3.0 Gy per day, 5 days per week, to 30 Gy)
Trial: 26148819
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter defibrillator (S-ICD) system
Trial: 26149600
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine 20 mL injected bilaterally into the fascial plane between the multifidus and longissimus muscles
Trial: 26150440
Drug: R-CHOP-14 at
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP-14 at end of treatment with central review
Trial: 26152560
Drug: Catheter Contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter Contact Force (CF) ≥10 g
Trial: 26152560
Drug: Increasing CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing CF at a location where initial CF was <10 g and CF increased ≥4.5 g in sinus rhythm or ≥8 g in atrial fibrillation
Trial: 26152560
Drug: Increasing CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing CF at a location with initial CF <10 g and CF increased ≥8 g
Trial: 26152560
Drug: Initial CF
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial CF ≥10 g
Trial: 26153272
Drug: High-sensitivity C-reactive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity C-reactive protein, soluble E-selectin, and soluble intercellular adhesion molecule-1 in type 2 diabetes
Trial: 26153726
Drug: Alpha-1 antitrypsin
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 antitrypsin augmentation therapy
Trial: 26153726
Drug: Matched PiZZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched PiZZ individuals not on augmentation therapy
Trial: 26153726
Drug: PiMZ participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PiMZ participants not on augmentation therapy
Trial: 26155941
Drug: AMG 208
RxNorm normalized name: AMG-208
DrugBank: AMG-208 (DB08079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 208 (oral MET inhibitor)
Trial: 26155957
Drug: Low albuminuria
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low albuminuria (LA, 10-29 mg/24 h)
Trial: 26155957
Drug: Normal albuminuria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal albuminuria (NA, <10 mg/24 h)
Trial: 26155957
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of anti-hyperglycaemic and anti-hypertensive agents
Trial: 26156652
Drug: High-dose chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemoradiotherapy (60 Gy in 30 fractions to tumour, 50 Gy in 30 fractions to elective lymph node volumes, 5 Gy endorectal brachytherapy boost, and oral tegafur-uracil 300 mg/m(2) every weekday for 6 weeks)
Trial: 26156652
Drug: High-dose chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemoradiotherapy
Trial: 26158159
Drug: S-1 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 combination with oxaliplatin and oral leucovorin (SOL regimen)
Trial: 26160357
Drug: Constant 24-h
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant 24-h infusion (16.5 μg/day)
Trial: 26160357
Drug: Constant 7-day
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant 7-day infusion (25.5 μg/day in Cohort 2)
Trial: 26160357
Drug: 7-day escalation
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day escalation regimen (ranging from 7 to 58.5 μg/day in Cohort 1)
Trial: 26160357
Drug: 7-day escalation
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day escalation regimen (25.5-58.5 μg/day in Cohort 3)
Trial: 26160744
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment (oseltamivir or zanamivir) in 474 patients.
Trial: 26160880
Drug: Panobinostat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (10 mg) combined with idarubicin (8 mg/m(2) iv days 1-3) and cytarabine (100 mg/m(2) iv days 1-7) during induction, followed by panobinostat maintenance (40 mg po 3 days/week) every other week until progression.
Trial: 26160880
Drug: Panobinostat monotherapy
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat monotherapy during maintenance phase for patients with persistent minimal residual disease.
Trial: 26161450
Drug: TNFα soluble
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNFα soluble receptors 1 (TNFα-sR1)
Trial: 26161450
Drug: TNFα soluble
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNFα soluble receptors 2 (TNFα-sR2)
Trial: 26161618
Drug: AXL1717, 390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXL1717, 390 mg BID for four weeks (RP2D)
Trial: 26163041
Drug: Early clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early clopidogrel therapy (initiation within 24 hours of hospital admission)
Trial: 26163041
Drug: Early clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early clopidogrel therapy
Trial: 26163041
Drug: Early clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early clopidogrel therapy in urban hospitals
Trial: 26163041
Drug: Early clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early clopidogrel therapy in rural hospitals
Trial: 26168005
Drug: Antibiotic prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescriptions resulting from influenza-attributable GP episodes
Trial: 26170136
Drug: Ombitasvir (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombitasvir (25 mg), Paritaprevir (150 mg), and Ritonavir (100 mg) once daily for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis)
Trial: 26171276
Drug: V1512 (melevodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V1512 (melevodopa 100 mg/carbidopa 25 mg)
Trial: 26171276
Drug: L-dopa 100
RxNorm normalized name: L-DOPA 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa 100 mg/carbidopa 25 mg
Trial: 26171276
Drug: V1512 or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V1512 or L-dopa/carbidopa in combination with entacapone 200 mg
Trial: 26172064
Drug: Instrumental activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental activities of daily living
Trial: 26172205
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal mitomycin C (PL-MLP) at doses of 0.5-3.5 mg/kg every 4 weeks for up to 12 cycles
Trial: 26175532
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to geriatrics or physical/occupational therapy
Trial: 26176325
Drug: K+D group
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+D group (90 μg of vitamin K2 and 10 μg of cholecalciferol)
Trial: 26176325
Drug: D group
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D group (10 μg of cholecalciferol)
Trial: 26176329
Drug: Anti-SAP antibody
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-SAP antibody infusion after CPHPC treatment
Trial: 26176329
Drug: CPHPC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPHPC treatment
Trial: 26176329
Drug: Anti-SAP antibody
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-SAP antibody infusion
Trial: 26176493
Drug: Low vitamin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vitamin D levels (<30 ng/ml)
Trial: 26176493
Drug: Normal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal vitamin D levels (≥30 ng/ml)
Trial: 26176696
Drug: Lead-in therapy
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead-in therapy with intravenous silibinin 20 mg/kg/day for 14 days followed by triple-therapy (peginterferon-ribavirin and telaprevir) for 12 weeks, and peginterferon-ribavirin alone for 36 weeks.
Trial: 26176696
Drug: Lead-in therapy
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead-in therapy with intravenous silibinin
Trial: 26178526
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg/d for 3 months
Trial: 26178723
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations <50 nmol/L
Trial: 26179200
Drug: Emactuzumab 900
RxNorm normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab 900 mg, 1350 mg, or 2000 mg every 2 weeks (dose-escalation phase) and 1000 mg every 2 weeks (dose-expansion phase)
Trial: 26180085
Drug: ASK1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASK1 inhibitor (GS-444217 delivered in chow) - early intervention (2-8 weeks after STZ)